BGNE240816P100000
- 3.50
- 0.000.00%
BeiGene Newsroom
BeiGene's Strong Financial and Clinical Prospects Solidify Buy Rating
BeiGene Second Quarter 2024 Earnings: Beats Expectations
Bank of America Securities: Reaffirmed Beigene's "Neutral" rating, with a target price increased to HKD 109.6.
Bank of America Securities released a research report reaffirming its neutral rating on Beigene (06160), and raised the target price from HKD 92.09 to HKD 109.6 due to intense competition and price pressure in the mainland market. The bank raised its sales forecast for the company this year by 10% based on the strong overseas sales of zanubrutinib, and also raised its sales forecast for next year and the year after by 17% and 20%, respectively. At the same time, the bank raised its sales and administrative expense forecasts for the company from this year to 2026, reflecting increased global market promotion activities. The report stated that the company's revenue and product revenue in the second quarter increased by 56% and 66% year-on-year, respectively, mainly from zanubrutinib.
Bocom Intl: Maintains 'buy' rating on Beigene (06160) with a target price of HKD 156.
Bocom Intl has raised the peak global sales forecast for Zejula from 4.4 billion to 5.2 billion.
[Brokerage Focus] BOCOM Intl raised Beigene (06160) target price by 23.8%, indicating that its new wave of innovative achievements is ready to be released.
According to the research report released by Bocom intl, Beigene (06160) achieved a adjusted non-GAAP operating profit of 0.048 billion US dollars (same below) in 2Q24, successfully turned losses into profits (2Q23: 0.193 billion). The bank raised the global sales peak forecast of zebutinib from 4.4 billion to 5.2 billion. The bank pointed out that a new wave of innovative achievements is waiting to be released: 1) Sonrotoclax (Bcl-2) first registration clinical study (global single-arm II phase treatment r/rMCL) has completed enrollment and is expected to complete follow-up, data cleaning and market application declaration in about a year, and the bank expects to
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Citigroup Maintains Buy on BeiGene, Raises Price Target to $288
BeiGene Analyst Ratings
Health Check: How Prudently Does BeiGene (NASDAQ:BGNE) Use Debt?
BeiGene's Brukinsa Drives Strong Growth and Justifies Buy Rating
Express News | Beigene : Leerink Partners Raises Target Price to $290 From $267
Beyond the Balance Sheet: What SWOT Reveals About BeiGene Ltd (BGNE)
Lyon reiterates its "outperform" rating on Beigene and raises its target price to HKD 148.4.
Lyon released a research report stating that after Beigene (06160) announced its performance, it revised its forecast and raised its target price from HKD 139.7 to HKD 148.4, reiterating the 'outperform' rating. The company's second-quarter revenue grew 56.1% YoY, exceeding expectations, due to the good momentum of its BTK project overseas. In addition, Brukinsa's sales in Beigene increased by 106.8% YoY, and the market share in the USA increased to 29.4%. The bank mentioned that the registration intention trial of the group's Bcl2 and the progress of its first B7H3ADC are worth paying attention to and will continue.
Some pharmaceutical stocks are rising against the market, and Beigene (06160) is up 5.03%. Institutions point to the pharmaceutical sector entering a value investment range.
Some pharmaceutical stocks bucked the trend, with BeiGene (06160) rising 5.03%, Shandong Xinhua Pharmaceutical (00719) rising 3.61%, Hansoh Pharma (03692) rising 2.38%, Joinn Laboratories (06127) rising 2.22%, and CanSinoBio (06185) rising 1.59%. News-wise, China International Capital Corporation released research reports stating that after 3 years of systematic adjustments, the pharmaceutical sector has entered the value investment range. Along with the gradual stabilization of domestic policies and the introduction of policies related to innovative drugs, the domestic innovative drug industry chain and overseas expansion are worth paying attention to in the second half of 2024.
Lyon: Reaffirmed BeiGene (06160) with an "outperform" rating and a target price of HKD 148.4.
Lyon's intention to register for beigene Bcl2 and the progress of the company's first B7H3 ADC are worth paying attention to.
BeiGene Narrows H1 Loss on Higher Product Sales; Hong Kong Shares Gain 3%
Beigene (06160) rose more than 3% against the market, with a 61% increase in revenue in the first half of the year. After the performance report, the target price was raised by Lian.
Beigene (06160) morning stock price rose against the market, as of press time, reported HKD 106.7, up 3.09%, with a turnover of HKD 33.6608 million. In terms of news, the total income for the six months ended June 30, 2024 reached 1.681 billion yuan (USD, the same below), a year-on-year increase of 61%, of which net product income reached 1.668 billion yuan, a year-on-year increase of 73%; GAAP operating losses fell by 47%. As for the second quarter, total revenue reached 0.929 billion yuan, a year-on-year increase of 56%, mainly due to the sales growth of Baiyuzhe in the United States and Europe, which increased by 1
Beigene's total revenue in the second quarter reached $0.929 billion, a year-on-year increase of 56%.
Beigene (06160) announced that total revenue reached $929 million, a year-on-year increase of 56%, as of June 30, 2024 for the three months. GAAP operating losses decreased and non-GAAP operating profit was achieved. Gross profit was $791 million, an increase of 58.44% year-on-year, and net losses were $120 million, a decrease of 68.41% year-on-year. Research and development expenses were $454 million, up 7.5% year-on-year. Baiyuzhe's global sales reached $637 million, a year-on-year increase of 107%, enhancing its leading position in the field of hematology. BCL2 inhibitor.
Buy Rating for BeiGene Backed by Brukinsa's Market Growth and Strong Financial Outlook
BeiGene Ltd Announces Proposed Domicile Change